

Clinical Policy: Iptacopan (Fabhalta)

Reference Number: LA.PHAR.656

Effective Date: 08.29.24

Last Review Date: 05.24.24 09.13.24

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Iptacopan (Fabhalta®) is a complement inhibitor of factor B.

FDA Approved Indication(s)

Fabhalta is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Louisiana Healthcare Connections that Fabhalta is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):

1. Diagnosis of PNH;
2. Prescribed by or in consultation with a hematologist;
3. Age \geq 18 years;
4. Flow cytometry shows detectable glycosylphosphatidylinositol (GPI)-deficient hematopoietic clones or \geq 10% PNH cells;
5. Documentation of hemoglobin $<$ 10 g/dL;
6. Fabhalta is not prescribed concurrently with another FDA-approved product for PNH (e.g., Soliris®, Ultomiris®, Empaveli®; Voydeya™; Bkemv™);
7. Dose does not exceed 400 mg (2 capsules) per day.

Approval duration: 6 months

Formatted: Font: Bold

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

II. Continued Therapy

A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):

- a. 1. Currently receiving medication via Louisiana Healthcare Connections or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters:
 - a. Improved measures of intravascular hemolysis or extravascular hemolysis (e.g., normalization of ~~LDH~~lactate dehydrogenase, reduced absolute reticulocyte count);
 - b. Reduced need for red blood cell transfusions;
 - c. Increased or stabilization of hemoglobin levels;
 - d. Less fatigue;
 - e. Improved health-related quality of life;
 - f. Fewer thrombotic events;
3. Fabhalta is not prescribed concurrently with another FDA-approved product for PNH (e.g., Soliris, Ultomiris, Empaveli, ~~Voydeya~~, ~~Bkemy~~);
4. If request is for a dose increase, new dose does not exceed 400 mg (2 capsules) per day.

Approval duration: **6 months**

Formatted: Font: Bold

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer LA PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

GPI: glycosylphosphatidylinositol

~~LDH: lactate dehydrogenase~~

PNH: paroxysmal nocturnal hemoglobinuria

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): serious hypersensitivity to iptacopan or any of the excipients; initiation in patients with unresolved serious infection caused by encapsulated bacteria,

Formatted: Number of columns: 1

Formatted: Indent: First line: 0.25"

CLINICAL POLICY

Iptacopan



including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type B

- Boxed warning(s): serious infections caused by encapsulated bacteria

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
PNH	200 mg PO BID with or without food	400 mg/day

VI. Product Availability

Capsule: 200 mg

VII. References

1. Fabhalta Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; ~~December 2023~~ March 2024. Available at <https://www.fabhalta-hcp.com/>. Accessed ~~December 19, 2023~~ May 15, 2024.
2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Blood* 2005; 106(12):3699-3709. Doi:10.1182/blood-2005-04-1717.
3. Borowitz MJ, Craig FE, DiGiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. *Cytometry Part B (Clinical Cytometry)*. 2010; 78B: 211-230.
4. ClinicalTrials.gov. NCT04820530. Study of efficacy and safety of twice daily oral iptacopan (LNP023) in adult PNH patients who are naïve to complement inhibitor therapy (APPOINT-PNH). Available at www.clinicaltrials.gov. Accessed ~~December 19, 2023~~ May 15, 2024.
5. ClinicalTrials.gov. NCT04558918. Study of efficacy and safety of twice daily oral LNP023 in adult PNH patients with residual anemia despite anti-C5 antibody treatment (APPLY-PNH). Available at www.clinicaltrials.gov. Accessed ~~December 19, 2023~~ May 15, 2024.

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted to Local Policy	05.24.24	<u>07.29.24</u>
<u>Added Voydeya and Bkemy to the list of therapies that Fabhalta should not be prescribed concurrently with; references reviewed and updated.</u>	<u>09.13.24</u>	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

CLINICAL POLICY

Iptacopan



The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.